A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of BGC20-1259 in patients with mild to moderate probable Alzheimer’s Disease

Update Il y a 4 ans
Reference: EUCTR2008-003659-63

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of BGC20-1259 (12.5 mg, 25 mg and 50 mg qd) administered for 6 months versus matched placebo


Inclusion criteria

  • Alzheimer's disease

Links